Lifecore Biomedical (NASDAQ:LFCR) Coverage Initiated by Analysts at KeyCorp

Key Points

• KeyCorp has initiated coverage on Lifecore Biomedical (NASDAQ:LFCR) with a sector weight rating, following similar coverage from other firms such as William Blair, which assigned an outperform rating.
• Lifecore Biomedical reported a quarterly loss of ($0.10) earnings per share, slightly missing expectations, while its revenue reached $36.44 million, exceeding analyst forecasts.
• Institutional investors own 83.36% of Lifecore Biomedical’s stock, with several firms like MIRAE ASSET GLOBAL increasing their holdings recently.

KeyCorp initiated coverage on shares of Lifecore Biomedical (NASDAQ:LFCR - Free Report) in a research note released on Wednesday morning, Marketbeat Ratings reports. The firm issued a sector weight rating on the stock. KeyCorp also issued estimates for Lifecore Biomedical's Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.46) EPS.

LFCR has been the subject of a number of other research reports. William Blair initiated coverage on shares of Lifecore Biomedical in a report on Wednesday, May 21st. They issued an "outperform" rating for the company. Wall Street Zen upgraded shares of Lifecore Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Lifecore Biomedical Trading Down 1.3%

Shares of LFCR traded down $0.10 during trading on Wednesday, reaching $7.20. 65,621 shares of the company traded hands, compared to its average volume of 209,702. Lifecore Biomedical has a twelve month low of $4.33 and a twelve month high of $8.85. The stock has a market cap of $269.16 million, a PE ratio of -5.49 and a beta of 0.64. The stock has a 50-day simple moving average of $7.60 and a 200-day simple moving average of $6.95. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. The company had revenue of $36.44 million for the quarter, compared to analyst estimates of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, analysts anticipate that Lifecore Biomedical will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legion Partners Asset Management LLC grew its holdings in Lifecore Biomedical by 49.3% during the 4th quarter. Legion Partners Asset Management LLC now owns 4,431,823 shares of the company's stock worth $32,928,000 after acquiring an additional 1,463,414 shares in the last quarter. Greenhaven Road Investment Management L.P. grew its holdings in Lifecore Biomedical by 2.2% during the 2nd quarter. Greenhaven Road Investment Management L.P. now owns 3,694,832 shares of the company's stock worth $30,002,000 after acquiring an additional 78,686 shares in the last quarter. Geode Capital Management LLC grew its holdings in Lifecore Biomedical by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 775,493 shares of the company's stock worth $6,299,000 after acquiring an additional 24,995 shares in the last quarter. Grizzlyrock Capital LLC acquired a new position in Lifecore Biomedical during the 2nd quarter worth approximately $5,964,000. Finally, Invesco Ltd. acquired a new position in Lifecore Biomedical during the 2nd quarter worth approximately $3,081,000. Institutional investors and hedge funds own 83.36% of the company's stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.